Page last updated: 2024-12-07

bosentan anhydrous

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID104865
CHEMBL ID957
CHEBI ID51450
SCHEMBL ID4218
MeSH IDM0585634

Synonyms (95)

Synonym
AC-148
CHEBI:51450 ,
bosentanum
4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide
unii-xul93r30k2
xul93r30k2 ,
HY-A0013
ro-47-0203
tracleer
ro-47-0203/039
ro-47-0203/029
PDSP2_001714
benzenesulfonamide, 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-
4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide
bosentan [usan:inn:ban]
ro 47-0203
ro 47-0203/039
bosentan (inn)
147536-97-8
D07538
PDSP1_001731
bosentan
4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
bosentan anhydrous
p-tert-butyl-n-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
DB00559
NCGC00167440-01
HMS2090N14
CHEMBL957 ,
ro-470203029
ro-47-0203-029
anhydrous bosentan
L001086
FT-0658809
4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2''-bipyrimidin)-4-yl) benzenesulfornamide
4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2''-bipyrimidin-4-yl]benzenesulfonamide
bdbm50061101
4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide
A808658
4-tert-butyl-n-[6-(2-hydroxyethyloxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]benzenesulfonamide
dtxsid7046627 ,
cas-147536-97-8
tox21_112444
dtxcid5026627
BCP9000445
S4220
n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide
174227-18-0
bosentan [mi]
bosentan [who-dd]
bosentan [inn]
AM84442
CS-0381
AKOS015852063
gtpl3494
CCG-221182
SCHEMBL4218
NCGC00167440-02
tox21_112444_1
KS-5062 ,
AB01275536-01
4-(tert-butyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulfonamide
4-tert-butyl-n-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-benzenesulfonamide
GJPICJJJRGTNOD-UHFFFAOYSA-N
4-tert butyl-n-[4-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)pyrimidin-6-yl]benzenesulphonamide
B5118
4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide
sr-05000001532
SR-05000001532-4
HMS3652F15
actelion
SR-05000001532-2
SR-05000001532-1
4-(1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide
K86 ,
J-008366
HMS3715N05
benzenesulfonamide, 4-(1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-
SW199648-3
4-tert-butyl-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
BCP05202
Q419769
Z1530532762
1174918-31-0
4-(tert-butyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide
4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzenesulfonamide
SB17356
HMS3750A13
W18800
147536-97-8 (free)
EN300-120648
4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl]benzene-1-sulfonamide
BB164259
STARBLD0043886

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" There were no adverse events except for a transient decrease in systemic blood pressure."( Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?
Gerbes, AL; Gülberg, V; Kuntzen, C, 2005
)
0.33
" We hypothesized that bosentan is safe and well tolerated in patients with Eisenmenger physiology."( Safety and tolerability of bosentan in adults with Eisenmenger physiology.
Cramer, D; Gatzoulis, MA; Gibbs, JS; Harries, C; Li, W; Mikhail, GW; Rogers, P; Ward, S, 2005
)
0.33
" No major adverse events or significant liver enzyme elevations were observed."( Safety and tolerability of bosentan in adults with Eisenmenger physiology.
Cramer, D; Gatzoulis, MA; Gibbs, JS; Harries, C; Li, W; Mikhail, GW; Rogers, P; Ward, S, 2005
)
0.33
"Bosentan was safe and well tolerated in adults with Eisenmenger physiology both at initiation and after 3 months of oral therapy."( Safety and tolerability of bosentan in adults with Eisenmenger physiology.
Cramer, D; Gatzoulis, MA; Gibbs, JS; Harries, C; Li, W; Mikhail, GW; Rogers, P; Ward, S, 2005
)
0.33
"In view of the shortcomings of the current system for postmarketing drug surveillance that is based on voluntary spontaneous adverse drug reaction (ADR) reporting, new approaches are needed."( Risk management strategies in the postmarketing period : safety experience with the US and European bosentan surveillance programmes.
Beacham, S; Bouley, L; Edfjall, C; Herrmann, P; Kempff, M; Oster, L; Raineri, M; Segal, ES; Valette, C; van Lierop, C, 2005
)
0.33
"The addition of a long-acting prostacyclin analogue via the inhaled route might be a safe and effective strategy to optimize therapy in PAH patients on bosentan."( Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
Channick, RN; Olschewski, H; Rubin, LJ; Seeger, W; Staub, T; Voswinckel, R, 2006
)
0.33
" In the remaining 11 patients, inhaled treprostinil was safe and well tolerated."( Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
Channick, RN; Olschewski, H; Rubin, LJ; Seeger, W; Staub, T; Voswinckel, R, 2006
)
0.33
"Bosentan was safe and well tolerated in adults with CHD related PAH during 12 months of treatment."( Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect.
Argiento, P; Badagliacca, R; Calabrò, R; D'Alto, M; Fedele, F; Ferrante, F; Mancone, M; Poscia, R; Romeo, E; Russo, MG; Santoro, G; Sarubbi, B; Vizza, CD, 2007
)
0.34
"Bosentan appears to be safe and well tolerated in adults with pulmonary arterial hypertension associated with congenital heart disease or Eisenmenger's syndrome during mid- to long-term follow-up."( Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
Diller, GP; Dimopoulos, K; Gatzoulis, MA; Gibbs, JS; Harries, C; Kaya, MG; Koltsida, E; Li, W; Uebing, A, 2007
)
0.34
" Patients tolerated the treatment well, and there were no severe adverse events or deaths."( Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonar
Aubert, JD; Domenighetti, G; Fischler, M; Geiser, T; Huber, L; Rochat, T; Speich, R; Treder, U; Ulrich, S, 2007
)
0.34
" Twelve patients (13%) experienced at least 1 adverse event."( Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension.
Cheng, XS; Dalton, BS; Gu, H; Jing, ZC; Pan, X; Shen, JY; Strange, G; Wang, Y; Xiang, MX; Yang, YJ; Yang, ZK; Yao, H; Zhang, ZL; Zhao, DB; Zhou, DX; Zhu, XY, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Bosentan, an endothelin A/B receptor antagonist, improved the patient's hemodynamic parameters and abolished his syncope without adverse effects."( Efficacy and safety of bosentan treatment for portopulmonary hypertension associated with syncope.
Aizawa, Y; Ito, E; Maie, K; Ohno, Y; Sato, A; Tanabe, Y; Yoshida, T, 2011
)
0.37
" There were no discontinuations from bosentan owing to adverse events."( Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
Clarke, B; Griffiths, L; Mahadevan, VS; Monfredi, O, 2011
)
0.37
" We undertook the present study to investigate whether PAH treatment is safe in these patients and might attenuate hemodynamic progression."( Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure.
Aberer, E; Brodmann, M; Graninger, W; Hesse, C; Kovacs, G; Kqiku, X; Maier, R; Olschewski, H; Rubin, L; Scheidl, S; Tröster, N, 2012
)
0.38
" No relevant adverse effects were reported."( Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure.
Aberer, E; Brodmann, M; Graninger, W; Hesse, C; Kovacs, G; Kqiku, X; Maier, R; Olschewski, H; Rubin, L; Scheidl, S; Tröster, N, 2012
)
0.38
" Bosentan might be safe and effective to attenuate these changes."( Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure.
Aberer, E; Brodmann, M; Graninger, W; Hesse, C; Kovacs, G; Kqiku, X; Maier, R; Olschewski, H; Rubin, L; Scheidl, S; Tröster, N, 2012
)
0.38
"  Treatment with bosentan is both safe and effective in patients with both simple and complex forms of ES."( Efficacy and safety of bosentan in adults with simple and complex Eisenmenger's syndrome.
Aboulhosn, J; Houser, L; Miner, P; Williams, R,
)
0.13
"  Safety was assessed by the incidence of anticipated and unanticipated adverse events during the 6-month study period; specifically those relating to hepatic, renal, or hematological dysfunction as measured by monthly blood tests."( The safety and effects of bosentan in patients with a Fontan circulation.
Bowater, SE; Clift, PF; Thorne, SA; Weaver, RA,
)
0.13
" Two patients withdrew from the study (one for non-trial related reasons, one due to adverse events)."( The safety and effects of bosentan in patients with a Fontan circulation.
Bowater, SE; Clift, PF; Thorne, SA; Weaver, RA,
)
0.13
" Safety included evaluation of adverse events including aminotransferase abnormalities."( Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
Brady, D; Calderbank, M; Ivy, DD; Rosenzweig, EB; Takatsuki, S; Zuckerman, W, 2013
)
0.39
" On the other hand, ambrisentan shows a higher rate of other adverse events, such as nasal congestion and peripheral edema."( Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
Fedele, F; Pezzuto, B; Rubin, LJ; Vizza, CD, 2012
)
0.38
"Because most medications for pediatric pulmonary hypertension (PH) are used off label and based on adult trials, little information is available on pediatric-specific adverse events (AEs)."( Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients.
Feinstein, JA; Ivy, DD; Maxey, DM; Ogawa, MT, 2013
)
0.39
" Oral bosentan in CHD-PAH patients was safe and well tolerated."( Safety and tolerability evaluation of oral bosentan in adult congenital heart disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.
Guo, L; Liu, YJ; Xie, ZL, 2014
)
0.4
"The objective of this study was to evaluate the pharmacokinetic properties and adverse effect profile of single-dose oral bosentan, a dual endothelin receptor antagonist, in healthy cats."( Pharmacokinetics and preliminary safety data of a single oral dose of bosentan, a dual endothelin receptor antagonist, in cats.
Chang, CH; DeClue, A; Papich, MG; Puza, N; Reinero, C; Sharp, C; Yu, DH, 2014
)
0.4
" However, the most frequent side effect of bosentan is liver toxicity, which often requires dose reduction and discontinuation."( Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports.
Amuro, H; Ito, T; Nishizawa, T; Nomura, S; Ozaki, Y; Son, Y; Tamaki, T; Tanaka, A, 2014
)
0.4
" Thus, the addition of ursodeoxycholic acid to the treatment protocol is expected to be useful when liver toxicity emerges as a side effect of bosentan."( Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports.
Amuro, H; Ito, T; Nishizawa, T; Nomura, S; Ozaki, Y; Son, Y; Tamaki, T; Tanaka, A, 2014
)
0.4
"Hepatotoxicity is a major side effect of treatment with bosentan in patients with pulmonary hypertension (PH)."( Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension.
Favreau, N; Halank, M; Kovacs, P; Mössner, J; Rosendahl, J; Ruffert, C; Seyfarth, HJ; Tennert, C; Wirtz, H; Wittenburg, H,
)
0.13
" While all three ERAs are generally well-tolerated, they each have important adverse effects that need to be recognized and monitored."( Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
Aversa, M; Granton, J; Porter, S, 2015
)
0.42
"Although endothelin receptor antagonists (ERAs) including bosentan and ambrisentan are essential tools for the treatment of pulmonary arterial hypertension (PAH), each agent has a specific adverse effect with non-negligible frequency, ie, liver dysfunction for bosentan and peripheral edema for ambrisentan."( Secure Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat Portopulmonary Hypertension Minimizing Each Adverse Effect.
Hatano, M; Imamura, T; Kinugawa, K; Komuro, I; Maki, H; Muraoka, H; Yao, A, 2015
)
0.42
" Safety and tolerability were evaluated via treatment-emergent adverse events (AEs), serious AEs, growth, and laboratory measurements."( FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion.
Beghetti, M; Berger, RM; Bonnet, D; Dulac, Y; Efficace, M; Fraisse, A; Galiè, N; Haworth, SG; Ivy, DD; Jaïs, X; Kusic-Pajic, A; Miera, O; Rosenzweig, EB, 2016
)
0.43
" The model predicts that bosentan is safe at the considered dose under the assumed conditions upon 4 weeks exposure."( In Silico Modeling for the Prediction of Dose and Pathway-Related Adverse Effects in Humans From In Vitro Repeated-Dose Studies.
Bucher, J; Heinzle, E; Klein, S; Maggioni, S; Mauch, K; Mueller, D; Niklas, J; Noor, F; Shevchenko, V, 2016
)
0.43
" The following adverse events occurred in 5% or more of patients during the 52-week treatment period: upper respiratory tract infection (50."( Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study.
Asano, Y; Endo, H; Hamaguchi, Y; Ihn, H; Kawaguchi, Y; Kuwana, M; Motegi, SI; Sumida, T; Takehara, K; Tanaka, S, 2017
)
0.46
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" Safety end points included adverse events laboratory abnormalities."( Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
Alehan, D; Aykan, HH; Aypar, E; Ertugrul, İ; Karagöz, T, 2018
)
0.48
"Our study is the first study that showed that switch from bosentan to macitentan significantly improved exercise capacity in children and young adults with pulmonary arterial hypertension and is well tolerated without any adverse events."( Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
Alehan, D; Aykan, HH; Aypar, E; Ertugrul, İ; Karagöz, T, 2018
)
0.48
" The process was well tolerated with no adverse events associated with the process."( Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study.
Coghlan, C; Coghlan, JG; Dawson, A; Reddecliffe, S; Schreiber, BE, 2018
)
0.48
" Liver dysfunction is a major adverse effect of bosentan and may lead to discontinuation of therapy."( CHST3 and CHST13 polymorphisms as predictors of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.
Emoto, N; Hirata, KI; Horibata, S; Kumagai, S; Miyagawa, K; Nakayama, K; Suzuki, Y; Tsuji, G; Uemura, Y; Yorifuji, K, 2018
)
0.48
"We have recently reported that switch from bosentan to macitentan significantly improved exercise capacity in children and young adults with pulmonary arterial hypertension in a 24-week prospective study and well tolerated without adverse events."( Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
Alehan, D; Aykan, H; Aypar, E; Ertugrul, İ; Karagöz, T, 2020
)
0.56
" Safety end points included adverse events, laboratory abnormalities."( Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
Alehan, D; Aykan, H; Aypar, E; Ertugrul, İ; Karagöz, T, 2020
)
0.56
"Our study is the first study which showed that switch from bosentan to macitentan improved exercise capacity in children and young adults with pulmonary arterial hypertension significantly in the first 6 months and compared to baseline in 24 months and well tolerated without adverse events."( Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
Alehan, D; Aykan, H; Aypar, E; Ertugrul, İ; Karagöz, T, 2020
)
0.56
" However, liver dysfunction is a major side effect of bosentan treatment that could hamper the optimal management of patients with PAH."( Predictive model of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.
Emoto, N; Hatae, T; Horibata, S; Kumagai, S; Nakayama, K; Suzuki, Y; Tsuji, G; Uemura, Y; Yorifuji, K, 2020
)
0.56
"This systematic review and meta-analysis was conducted to identify if long-term bosentan is an effective and safe treatment for pulmonary arterial hypertension (PAH) regardless of type, including idiopathic PAH (IPAH), and PAH associated with congenital heart disease (APAH-CHD), connective tissue disease (APAH-CTD), and human immunodeficiency virus (APAH-HIV)."( Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
Chen, M; Du, HA; Kuang, HY; Li, Q; Yin, YH, 2021
)
0.62
" Adverse drug reactions were relatively mild."( Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
Chen, M; Du, HA; Kuang, HY; Li, Q; Yin, YH, 2021
)
0.62
" In addition, we conclude that long-term oral bosentan should be considered for patients with CTD to achieve a satisfactory exercise capacity, and for those with APAH-HIV to improve survivals, where more attention on adverse events is required."( Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
Chen, M; Du, HA; Kuang, HY; Li, Q; Yin, YH, 2021
)
0.62
" Hazard ratio (HR) was calculated for binary outcomes, including clinical worsening, discontinuation due to adverse events (AEs) and liver dysfunction."( Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
Chen, J; Guo, N; Parks, D; Tian, Z; Zhao, Q, 2022
)
0.72
" In addition, the histopathological examination showed severe toxic features of cardiac injury."( Cardioprotective effects of bosentan in 5-fluorouracil-induced cardiotoxicity.
Abdel-Gaber, SA; Hafez, SMNA; Khalaf, HM; Rahman, SAAE; Refaie, MMM, 2022
)
0.72
" However, when using bosentan, attention should be paid to adverse reactions such as abnormal liver function."( Efficacy and safety of bosentan in the treatment of persistent pulmonary hypertension of the newborn: a Metaanalysis.
Jia, JJ; Li, LX; Li, M; Wei, B; Yang, M, 2022
)
0.72
" Adverse events occurred in 45% (18/40), and hepatic dysfunction was occurred most frequently at 32."( Real-world effectiveness and safety of bosentan in Japanese patients with systemic sclerosis: A single-center retrospective study.
Endo, Y; Ishikawa, M; Motegi, SI; Sekiguchi, A; Uchiyama, A; Yamazaki, S, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" Integrating this prediction into the design of the first clinical protocols substantially improved the quality of the human pharmacokinetic data obtained."( Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data.
Coassolo, P; Jaeck, D; Lave, T; Schmitt, C; Ubeaud, G, 1995
)
0.29
" Average steady-state Cmax and Ctr were 2-2."( The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects.
Banken, L; Birnboeck, H; Nave, S; Schulz, R; Weber, C, 1999
)
0.3
" Cmax and tmax of both enantiomers did not change."( Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin.
Banken, L; Birnboeck, H; Schulz, R; Weber, C, 1999
)
0.3
"Several statistical regression models and artificial neural networks were used to predict the hepatic drug clearance in humans from in vitro (hepatocyte) and in vivo pharmacokinetic data and to identify the most predictive models for this purpose."( Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
Coassolo, P; Lavé, T; Schneider, G, 1999
)
0.3
" A pharmacokinetic study of CsA and BO was performed."( Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A.
Binet, I; Jones, R; Thiel, G; Wallnöfer, A; Weber, C, 2000
)
0.31
" Acute inhibition of both ETA and ETB receptors with bosentan dramatically prolonged 125I-ET-1 plasma half-life and shifted tissue uptake from lung to liver and kidneys."( Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade.
Barton, M; Burkhardt, M; Shaw, SG, 2000
)
0.31
" This study was conducted to investigate a possible pharmacokinetic interaction between bosentan and glyburide."( In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide.
Bodin, F; Clozel, M; Dingemanse, J; Treiber, A; van Giersbergen, PL, 2002
)
0.31
" The observed pharmacodynamic interaction between bosentan and glyburide in patients with chronic heart failure cannot be explained by a pharmacokinetic interaction."( In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide.
Bodin, F; Clozel, M; Dingemanse, J; Treiber, A; van Giersbergen, PL, 2002
)
0.31
"Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior."( General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.
Jusko, WJ; Mager, DE, 2001
)
0.31
"The present study was conducted to characterize the single- and multiple-dose pharmacokinetics of bosentan, a dual endothelin receptor antagonist, and to investigate a possible pharmacokinetic interaction with ketoconazole."( Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.
Dingemanse, J; Halabi, A; van Giersbergen, PL, 2002
)
0.31
" The pharmacokinetic parameters of bosentan and its metabolites were similar in both groups: geometric means for Cmax and AUC for bosentan were 2534 and 1980 ng/ml and 11,957 and 10,781 ng."( Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
Bodin, F; Dingemanse, J; Popescu, G; van Giersbergen, PL, 2003
)
0.32
"To investigate in vivo the mutual pharmacokinetic interactions between bosentan and simvastatin, a CYP3A4 substrate."( Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin.
Dingemanse, J; Schaarschmidt, D; van Giersbergen, PL, 2003
)
0.32
" The pharmacokinetic parameters of bosentan and its metabolites were not influenced by concomitant treatment with simvastatin: areas under the plasma concentration-time curve over one administration interval of 12 hours (AUC(tau)) [geometric mean and 95% CI] were 4586 (3719-5656) and 4928 (3945-6156) micro g * h/L."( Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin.
Dingemanse, J; Schaarschmidt, D; van Giersbergen, PL, 2003
)
0.32
" Pharmacokinetic and hemodynamic parameters were obtained at baseline and after 12 weeks of treatment."( Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.
Barst, RJ; Bingaman, D; Dingemanse, J; Doran, A; Gaitonde, M; Ivy, D; Nguyen, N; Schmitt, K; van Giersbergen, PL; Widlitz, A, 2003
)
0.32
" Results from both series of experiments point to inhibition of active bosentan uptake into the liver by cyclosporin A as the major underlying mechanism for this pharmacokinetic interaction that is in line with reports on other oatp-transported drugs."( Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat.
Clozel, M; Delahaye, S; Schneiter, R; Treiber, A, 2004
)
0.32
" The authors report on the use of bosentan (125 mg twice daily) and its pharmacokinetic monitoring in a 19-year-old woman with PH and end-stage renal disease secondary to scleroderma."( Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD.
Budde, K; Dingemanse, J; Hocher, B; Liefeldt, L; Neumayer, HH; Rudolph, B; van Giersbergen, PL; Walde, T, 2004
)
0.32
" Pharmacokinetic profiles of bosentan and its pharmacologically active hydroxy metabolite, Ro 48-5033, were determined after each dose of bosentan."( Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects.
Dingemanse, J; van Giersbergen, PL, 2005
)
0.33
"The aim of this study was to systematically investigate the mutual pharmacokinetic interactions in healthy volunteers between sildenafil, a phosphodiesterase-5 inhibitor, and bosentan, a dual endothelin receptor antagonist, both approved for treating pulmonary arterial hypertension (PAH)."( Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
Burgess, G; Collings, L; Dingemanse, J; Hoogkamer, H, 2008
)
0.35
"In healthy volunteers, there is a mutual pharmacokinetic interaction between bosentan and sildenafil that may influence the dosage of each drug in a combination treatment."( Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
Burgess, G; Collings, L; Dingemanse, J; Hoogkamer, H, 2008
)
0.35
" Tadalafil is mainly metabolized by cytochrome P450 (CYP) 3A4, and as bosentan induces CYP2C9 and CYP3A4, a pharmacokinetic interaction is possible between these agents."( Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
Darstein, C; Dingemanse, J; Mitchell, MI; Phillips, DL; Wrishko, RE; Yu, A, 2008
)
0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"The purpose of this study was to evaluate the mechanisms responsible for the pharmacokinetic variability of bosentan utilizing rats with liver dysfunction induced by 7-day bile duct ligation (BDL)."( Mechanisms responsible for the altered pharmacokinetics of bosentan: analysis utilizing rats with bile duct ligation-induced liver dysfunction.
Hashimoto, Y; Horiuchi, I; Ichida, F; Miyawaki, T; Mori, YI; Taguchi, M, 2009
)
0.35
" Blood samples were taken for pharmacokinetic purposes."( Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study.
Acar, P; Barst, RJ; Beghetti, M; Berger, RM; Bonnet, D; Dingemanse, J; Fraisse, A; Galiè, N; Haworth, SG; Ivy, DD; Jais, X; Kusic-Pajic, A; Morganti, A; Schulze-Neick, I, 2009
)
0.35
"25, co-administration of oral treprostinil and bosentan did not result in a pharmacokinetic interaction for either agent."( Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers.
Dingemanse, J; Gotzkowsky, SK; Lai, A; Laliberte, K; Mottola, D, 2010
)
0.36
"We aimed to investigate the extent of pharmacokinetic drug interactions between bosentan and a fixed combination of lopinavir/ritonavir."( Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
Dingemanse, J; Nilsson, PN; Patat, A; van Giersbergen, PL, 2010
)
0.36
" The population pharmacokinetic parameters of bosentan were estimated by use of the NONMEM program, in which a one-compartment model with repetitive bolus dosing was parameterized in terms of the oral clearance (CL/F) and elimination rate constant (k)."( Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension.
Akita, C; Hashimoto, Y; Hirono, K; Horiuchi, I; Ichida, F; Kato, Y; Miyawaki, T; Nakamura, T; Nakayama, T; Saji, T; Taguchi, M; Yoshimura, N, 2011
)
0.37
"The objective of this study was to evaluate the pharmacokinetic properties and adverse effect profile of single-dose oral bosentan, a dual endothelin receptor antagonist, in healthy cats."( Pharmacokinetics and preliminary safety data of a single oral dose of bosentan, a dual endothelin receptor antagonist, in cats.
Chang, CH; DeClue, A; Papich, MG; Puza, N; Reinero, C; Sharp, C; Yu, DH, 2014
)
0.4
"For both drugs, the peak plasma concentration was lower and the half-life was shorter than the known values in adults."( Pharmacokinetics of drugs for pediatric pulmonary hypertension.
Azuma, H; Kajihama, A; Kajino, H; Kamiyama, N; Maeda, J; Nakau, K; Oka, H; Sugimoto, M; Tasaki, Y; Yamagishi, H, 2016
)
0.43
"FUTURE-3, a phase III pediatric pharmacokinetic (PK) trial conducted to compare 2 bosentan dosing regimens in 64 patients with pulmonary arterial hypertension, offered the opportunity to compare dried blood spot (DBS)-derived data to plasma data."( Bosentan Pharmacokinetics in Pediatric Patients with Pulmonary Arterial Hypertension: Comparison of Dried Blood Spot and Plasma Analysis.
Dingemanse, J; Géhin, M; Sidharta, PN, 2016
)
0.43
" This method was successfully applied to a pharmacokinetic study of coadministeration of BOS and GLP in rats."( Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study.
Chen, M; Chen, Q; Hu, G; Pan, P; Song, W; Wang, S; Xu, T; Zheng, Z, 2016
)
0.43
" Using bosentan as an example, we demonstrate a new approach to estimate liver exposure based on observed systemic pharmacokinetics from clinical studies using physiologically based pharmacokinetic modeling."( A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects.
Di, L; El-Kattan, AF; Johnson, N; Kimoto, E; Li, R; Lin, J; Maurer, TS; Niosi, M; Riccardi, KA; Ryu, S; Tess, DA; Tremaine, LM; Yang, X, 2018
)
0.48
" To address this, we performed physiologically based pharmacokinetic (PBPK) modeling analyses for bosentan after its intravenous administration at different doses."( Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics.
Hisaka, A; Lee, W; Sato, M; Sugiyama, Y; Tanaka, Y; Tomaru, A; Toshimoto, K; Yoshikado, T, 2018
)
0.48
"The assay procedure was fully validated and successfully applied in pharmacokinetic interaction study of flibanserin with bosentan in rats."( A validated UPLC-MS/MS method for flibanserin in plasma and its pharmacokinetic interaction with bosentan in rats.
Al-Rashood, KA; Bajrai, AA; Ezzeldin, E; Iqbal, M; Rezk, NL, 2018
)
0.48
" Among them, compound 15 (TPN171) with subnanomolar potency for PDE5 and good selectivity over PDE6 was finally recognized as a potential drug candidate, and its pharmacokinetic profiles in rats and dogs are significantly improved compared to the starting compound (3)."( Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
Aisa, HA; Gong, X; He, Y; Jiang, H; Jiang, X; Li, J; Liu, Z; Shen, J; Shi, J; Suo, J; Tian, G; Wang, Y; Wang, Z; Wu, C; Wu, J; Xu, Y; Xu, Z; Yang, R; Yang, X; Zhang, R; Zhang, X; Zhu, W; Zou, X, 2019
)
0.51
" A target-mediated drug disposition (TMDD) pharmacokinetic (PK) model described the non-linearity in the PK of bosentan caused by its high receptor binding affinity with time-dependent varying receptor expression or reappearance."( Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists.
Dingemanse, J; Krause, A; Lehr, T; Volz, AK, 2019
)
0.51
" A physiologically based pharmacokinetic (PBPK) model incorporating the metabolites was developed to predict the effect of other strong and moderate CYP3A4 inhibitors and inducers."( Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
Dickinson, GL; Hall, SD; Kulanthaivel, P; Morse, BL; Posada, MM; Turner, PK, 2020
)
0.56
" SIGNIFICANCE STATEMENT: By incorporating saturable target binding, our physiologically based pharmacokinetic (PBPK) model predicted in vivo target occupancy of bosentan based only on the blood concentration-time profiles obtained from a wide range of doses."( Revisiting Nonlinear Bosentan Pharmacokinetics by Physiologically Based Pharmacokinetic Modeling: Target Binding, Albeit Not a Major Contributor to Nonlinearity, Can Offer Prediction of Target Occupancy.
Aoki, Y; Koyama, S; Lee, W; Sugiyama, Y; Toshimoto, K, 2021
)
0.62
" To investigate and potentially fulfill an unmet need in pediatric patients with PAH, pharmacokinetic (PK) data were explored in a pediatric phase Ib/II study and pooled with prior phase III (pulmonary arterial hypertension and response to tadalafil [PHIRST-1]) adult data to develop the first population PK model for tadalafil in pediatric patients with PAH."( Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.
Ferguson-Sells, L; Li, B; Small, D; Velez de Mendizabal, N, 2022
)
0.72
"The study reported here aimed to develop and optimize the S-SNEDDS tablet of bosentan (BOS) and to investigate its pharmacokinetic and biodistribution properties."( Development and pharmacokinetic evaluation of Neusilin® US2-based S-SNEDDS tablets for bosentan: Fasted and fed states bioavailability, IVIS® real-time biodistribution, and ex-vivo imaging.
Olgac, S; Teksin, ZS; Timur, B; Yilmaz Usta, D, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" During endotoxin shock, this drug combination efficiently counteracts pulmonary hypertension and improves cardiac performance and splenic and renal blood flow."( The endothelin receptor antagonist, bosentan, in combination with the cyclooxygenase inhibitor, diclofenac, counteracts pulmonary hypertension in porcine endotoxin shock.
Hemsén, A; Lundberg, JM; Rudehill, A; Wanecek, M; Weitzberg, E, 1997
)
0.3
"To investigate the effects of the mixed endothelin receptor antagonist, bosentan, combined with the long-acting calcium channel blocker, amlodipine, compared to the angiotensin-converting enzyme inhibitor, cilazapril, on the progressive renal injury in spontaneous hypertensive rats (SHR) with diabetes."( Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes.
Chen, J; Gu, Y; Lin, F; Lin, S; Ma, J; Yang, H; Zhu, W, 2002
)
0.31
"Bosentan combined with amlodipine can offer similar renoprotective effects on that of cilazapril and may be a potent therapy to attenuate renal injury by reducing renal protein levels of TGF-beta1 in diabetes with a hypertensive state."( Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes.
Chen, J; Gu, Y; Lin, F; Lin, S; Ma, J; Yang, H; Zhu, W, 2002
)
0.31
" This retrospective, single-center, open-label study was designed to assess the efficacy of long-term, subcutaneously administered, treprostinil-based therapy alone or in combination with bosentan for the treatment of moderate-to-severe PAH."( Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
Benza, RL; Bourge, RC; Pamboukian, SV; Rayburn, BK; Tallaj, JA, 2008
)
0.35
"The authors review the basic pharmacology and potential for adverse drug-drug interactions (DDIs) of bosentan and ambrisentan, the 2 endothelin receptor antagonists currently approved for pulmonary arterial hypertension (PAH) treatment."( Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.
Allard, M; Dufton, C; Gillies, H; Regnault, J; Venitz, J; Zack, J, 2012
)
0.38
" Due to the above properties, bosentan has the potential to display drug-drug interaction with the co-administered drugs, either being a perpetrator or a victim."( Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: Physiological role of enzymes and transporters.
Srinivas, NR, 2016
)
0.43
" As such, more opportunities exist for drug-drug interactions between PAH-targeted medications and medications potentially used to treat comorbid conditions."( Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension.
Alotaibi, M; Fernandes, TM; Hoang, HB; Kim, NH; Lombardi, S; Papamatheakis, DG; Poch, DS; Rodriguez, C; Wu, S; Yang, JZ, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" The absolute bioavailability was 50% and appeared to decrease with doses above 600 mg."( Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.
Birnboeck, H; Hopfgartner, G; Jones, CR; Jonkman, JH; Peeters, PA; Schmitt, R; van Marle, SP; Weber, C, 1996
)
0.29
" The oral bioavailability of bosentan was 43% to 48%, with a small interindividual variability of 20%."( Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.
Birnboeck, H; Eggers, H; Hopfgartner, G; Jonkman, JH; Meyer, J; Schmitt, R; van Marle, S; Viischer, HW; Weber, C, 1999
)
0.3
"The purpose of the study was to investigate the effect of food intake on the pharmacokinetics and metabolism as well as the relative bioavailability of bosentan."( Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
Bodin, F; Dingemanse, J; Kutz, K; van Giersbergen, P; Weidekamm, E, 2002
)
0.31
" Here we report an expansion of this work by substituting a variety of electron-withdrawing groups at the ortho position and evaluating their effects on oral bioavailability as well as structure-activity relationships."( Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
Berens, KL; Blok, N; Bourgoyne, AR; Brock, TA; Bui, H; Decker, ER; Dixon, RA; Holland, GW; Knowles, V; Wang, J; Wu, C; You, TJ, 2004
)
0.32
" The absolute bioavailability is about 50%."( Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
Dingemanse, J; van Giersbergen, PL, 2004
)
0.32
" These results suggest that YM598 has a high selectivity for native human ETA receptors against ETB receptors, and that YM598 is superior to atrasentan as an ETA receptor antagonist, with regard to pharmacological bioavailability in rats."( Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist.
Fujimori, A; Miyata, K; Noguchi, Y; Ohtake, A; Sasamata, M; Sato, S; Sudoh, K; Ukai, M; Yuyama, H, 2004
)
0.32
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" Clinical testing of an orally bioavailable endothelin antagonist has demonstrated benefit in PSA progression, markers of bone turnover, and pain in men with prostate cancer, but has not demonstrated significant improvement in survival or time to cancer progression."( Endothelin receptor antagonists in cancer therapy.
Lalich, M; Liu, G; McNeel, DG; Wilding, G, 2007
)
0.34
" EDHF was likely the sole mediator responsible for the direct effects of LPC on U-46619-vasoconstriction, whereas the augmented vasoconstrictor responses following LPC washout may in part be related to an increase in ET-1, and a striking reduction in the bioavailability of NO."( The ischemic metabolite lysophosphatidylcholine increases rat coronary arterial tone by endothelium-dependent mechanisms.
Bai, N; Laher, I; MacLeod, KM; Rodrigues, B; So, J; Zhang, R, 2009
)
0.35
" We also investigated the changes in the central carbon metabolism of HepaRG cells exposed to orally bioavailable concentrations of both drugs."( In Silico Modeling for the Prediction of Dose and Pathway-Related Adverse Effects in Humans From In Vitro Repeated-Dose Studies.
Bucher, J; Heinzle, E; Klein, S; Maggioni, S; Mauch, K; Mueller, D; Niklas, J; Noor, F; Shevchenko, V, 2016
)
0.43
" The oral delivery of bosentan possesses several drawbacks such as low bioavailability (about 50%), short duration of action, frequent administration, hepatotoxicity and systemic hypotension."( Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: in vitro aerosolization, histological examination and in vivo pulmonary absorption.
Basalious, EB; ELGazayerly, ON; Hanna, LA, 2016
)
0.43
" But the solubility and bioavailability of this drug are poor, which has restricted the design and development of dosage forms for efficient and successful therapy."( Effect of amphiphilic graft co-polymer-carrier on physical stability of bosentan nanocomposite: Assessment of solubility, dissolution and bioavailability.
Chaudhari, PD; Kendre, PN, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" An absolute bioavailability study informed the hepatic and gastric availability."( Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
Dickinson, GL; Hall, SD; Kulanthaivel, P; Morse, BL; Posada, MM; Turner, PK, 2020
)
0.56
" Inhalable bosentan microparticles with the capability of delivery to the peripheral region of the lungs and enhanced bioavailability have been formulated for PAH."( Inhaled bosentan microparticles for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats.
Kang, JH; Kim, DW; Kim, JY; Kwon, YB; Lee, HJ; Oh, DW; Park, CW; Park, ES; Rhee, YS; Shin, DH, 2021
)
0.62
" Other covariate effects were that bosentan increased CL/F, V/F decreased with decreasing body weight, and bioavailability (F) decreased with increasing dose and decreasing age."( Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.
Ferguson-Sells, L; Li, B; Small, D; Velez de Mendizabal, N, 2022
)
0.72
"A one-compartment model parameterized in terms of F, absorption rate constant, CL/F, and V/F described the data well."( Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.
Ferguson-Sells, L; Li, B; Small, D; Velez de Mendizabal, N, 2022
)
0.72
"This study aimed to develop and optimize a self-nanoemulsifying drug delivery system (SNEDDS) of bosentan (BOS) to solve its poor oral bioavailability due to low water solubility."( Formulation development, optimization by Box-Behnken design, characterization, in vitro, ex-vivo, and in vivo evaluation of bosentan-loaded self-nanoemulsifying drug delivery system: A novel alternative dosage form for pulmonary arterial hypertension trea
Teksin, ZS; Timur, B; Usta, DY, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" However SX6C was more potent than ETs and the dose-response curve was significantly steeper and achieved a higher maximum."( Actions of endothelins and sarafotoxin 6c in the rat isolated perfused lung.
Lal, H; Williams, KI; Woodward, B, 1995
)
0.29
"375 mg given twice on the day before the once daily dosing regimen started."( The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects.
Banken, L; Birnboeck, H; Nave, S; Schulz, R; Weber, C, 1999
)
0.3
" Vascular segments were obtained in 34 patients who had undergone revascularization procedures, and isometric dose-response curves (DRCs) were constructed using the isolated tissue bath procedure as follows: 1) cumulative DRCs to norepinephrine; and 2) DRCs to acetylcholine (ACh) and sodium nitroprusside in the absence and presence of bosentan, BQ-123, or BQ-788."( Augmentation of endothelial function by endothelin antagonism in human saphenous vein conduits.
Anderson, TJ; Dumont, AS; Lovren, F; McNeill, JH; Sutherland, GR; Triggle, CR; Verma, S, 2001
)
0.31
" Following 10 weeks of bosentan treatment, vascular responses to norepinephrine (NE), ET-1, acetylcholine (ACh) were determined in vascular segments of renal arteries, both with and without the endothelium denuded, according to the following protocol: (1) a cumulative dose-response curve (DRC) to NE in the absence and presence of the nitric oxide synthase (NOS) inhibitor L-NAME (2) cumulative DRC to ET-1 and (3) cumulative DRC to ACh in precontracted arteries."( Chronic bosentan treatment improves renal artery vascular function in diabetes.
Arikawa, E; Dumont, AS; McNeill, JH; Verma, S, 2001
)
0.31
" In vitro endothelium-dependent and -independent responses to acetylcholine and sodium nitroprusside were assessed by constructing isometric dose-response curves in precontracted rings in the presence and absence of bosentan (endothelinA/B receptor antagonist) and BQ-123 (endothelinA antagonist) using isolated organ baths."( Endothelin blockade potentiates endothelial protective effects of ACE inhibitors in saphenous veins.
Anderson, TJ; Badiwala, M; Dumont, AS; Fedak, PW; Ko, L; Lovren, F; Maitland, A; Rao, V; Triggle, CR; Verma, S, 2002
)
0.31
" These results suggest that the applied dosing regimens may be appropriate to treat pediatric patients."( Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.
Barst, RJ; Bingaman, D; Dingemanse, J; Doran, A; Gaitonde, M; Ivy, D; Nguyen, N; Schmitt, K; van Giersbergen, PL; Widlitz, A, 2003
)
0.32
" After these 5 weeks of dosage increases, the INR became supratherapeutic for 3 weeks, resulting in a subsequent dosage decrease."( Bosentan and warfarin interaction.
Hood, EH; Murphey, LM,
)
0.13
" Bosentan for the treatment of secondary PH seems to be safe as well as effective in end-stage renal disease patients and no adjustment of the bosentan dosing regimen appears necessary."( Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD.
Budde, K; Dingemanse, J; Hocher, B; Liefeldt, L; Neumayer, HH; Rudolph, B; van Giersbergen, PL; Walde, T, 2004
)
0.32
" Ease of administration of bosentan with twice-daily oral dosing will provide many patients with pulmonary hypertension an option for treatment without the risks and discomforts of continuous intravenous medication."( Bosentan.
Channick, R; Chin, K, 2004
)
0.32
" No dosage adjustment in adults is required based on sex, age, ethnic origin and bodyweight."( Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
Dingemanse, J; van Giersbergen, PL, 2004
)
0.32
" Eight patients fully met the inclusion criteria and were eligible for therapy with bosentan given at the dosage of 62."( The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension.
Antonaci, S; Giannelli, G; Iannone, F; Lapadula, G; Marinosci, F, 2005
)
0.33
" Application of ET-1 to control and CIH-treated CBs produced long-lasting dose-dependent increases in f(x), although the dose-response curve showed a rightward-shift in the CIH-treated CBs."( Contribution of endothelin-1 to the enhanced carotid body chemosensory responses induced by chronic intermittent hypoxia.
Del Rio, R; Iturriaga, R; Rey, S, 2006
)
0.33
" Bosentan causes an increase of transaminases in about 10% of patients, but this effect is reversible on dosage reduction or discontinuing the medication."( [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
Hoeper, MM, 2006
)
0.33
" Oral bosentan was well tolerated and there was no episode of liver dysfunction that required adjustment of the bosentan dosage or discontinuance of therapy."( Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension.
Chen, JS; Chen, RJ; Hsu, HH; Ko, WJ; Kuo, SW; Lee, YC; Wang, JK; Wu, ET; Wu, MH, 2007
)
0.34
" The use of bosentan for vasculitis had not been reported in children before the treatment of our patient, so its dosage was based on that used to produce vasodilation in children with pulmonary hypertension."( Polyarteritis nodosa resistant to conventional treatment in a pediatric patient.
García-Consuegra, J; González-Fernández, MA, 2007
)
0.34
" In patients continuously treated for 4 months, during which the dosage of bosentan remained at 125 mg/day (n = 5) or increased to 250 mg/day (n = 5), the 4-week results remained unchanged."( Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
Fragiadaki, KG; Katsichti, P; Mavrikakis, M; Papamichael, C; Sfikakis, PP; Stamatelopoulos, KS; Stefanadis, C; Tousoulis, D, 2007
)
0.34
" All patients received bosentan at dosage of 62."( [Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan)].
Chialà, A; Covelli, M; Grattagliano, V; Lannone, F; Lapadula, G; Riccardi, MT,
)
0.13
"6%] and the area under the plasma concentration versus time curve over a dosing interval (AUC(tau)) by 62."( Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
Burgess, G; Collings, L; Dingemanse, J; Hoogkamer, H, 2008
)
0.35
"In healthy volunteers, there is a mutual pharmacokinetic interaction between bosentan and sildenafil that may influence the dosage of each drug in a combination treatment."( Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
Burgess, G; Collings, L; Dingemanse, J; Hoogkamer, H, 2008
)
0.35
" Dosage recommendations in adults and pediatrics are presented."( Review of bosentan in the management of pulmonary arterial hypertension.
Fraser, J; Gabbay, E; McNeil, K, 2007
)
0.34
" Since a recent randomized study showed no dose-response relationship, the target dose in future will be 20mg tid."( Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance.
Fischler, M; Huber, LC; Maggiorini, M; Speich, R; Spring, RM; Treder, U; Ulrich, S, 2008
)
0.35
" Therefore, in clinical practice, other features are likely to be of greater relevance when considering treatment, such as the potential for serious drug-drug interactions, convenience of dosing schedule, or rates of limiting side effects."( Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
Ewert, R; Kirch, W; Opitz, CF; Pittrow, D, 2008
)
0.35
" Because a remarkable elevation of mixed venous oxygen saturation was observed at the initiation of bosentan, the dosage of EPO was reduced in 7 patients (from 99."( Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol.
Akagi, S; Dan, K; Fujimoto, Y; Hisamatsu, K; Ikeda, E; Matsubara, H; Miyaji, K; Munemasa, M; Ohe, T; Tokunaga, N, 2008
)
0.35
" Further studies are needed to study the dose-response relationship of this effect and to characterize the role of endothelin receptor subtypes."( Effect of dual endothelin receptor blockade on ocular blood flow in patients with glaucoma and healthy subjects.
Garhöfer, G; Hommer, A; Karl, K; Resch, H; Schmetterer, L; Weigert, G; Wolzt, M, 2009
)
0.35
" A noncomparative, multicenter, phase III trial (FUTURE-1), which was primarily designed to investigate the pharmacokinetics of dispersible bosentan in pediatric patients, demonstrated that increasing the dosage of bosentan from 2 to 4 mg/kg twice daily was unlikely to result in increased exposure to bosentan."( Bosentan: in pediatric patients with pulmonary arterial hypertension.
Carter, NJ; Keating, GM, 2010
)
0.36
" Phentermine has been considered a relatively safe drug to treat obesity, and further investigation is needed to decide the safety and dosage of phentermine."( Pulmonary hypertension associated with use of phentermine.
Bang, WD; Chang, HJ; Cho, SS; Jang, JY; Joung, B; Kim, JY; Oh, CM; Yu, HT, 2010
)
0.36
" The population pharmacokinetic parameters of bosentan were estimated by use of the NONMEM program, in which a one-compartment model with repetitive bolus dosing was parameterized in terms of the oral clearance (CL/F) and elimination rate constant (k)."( Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension.
Akita, C; Hashimoto, Y; Hirono, K; Horiuchi, I; Ichida, F; Kato, Y; Miyawaki, T; Nakamura, T; Nakayama, T; Saji, T; Taguchi, M; Yoshimura, N, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" At termination, basilar arteries were collected and mounted on a wire myograph and cumulative dose-response curves to endothelin-1 (1-500 nM) and acetylcholine (1 nM-5 μm) were studied."( Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes.
Ergul, A; Li, W; Sachidanandam, K, 2011
)
0.37
" Bosentan (1E-7 M) significantly attenuated combined ET-1/NE dose-response curves in PA (93."( Combination of sildenafil and bosentan for pulmonary hypertension in a human ex vivo model.
Hoenicka, M; Hofmann, HS; Liebold, A; Neu, R; Potzger, T; Ried, M; Sziklavari, Z; Szöke, T, 2014
)
0.4
" At termination, basilar arteries were collected and cumulative dose-response curves to ET-1 (0."( Late dual endothelin receptor blockade with bosentan restores impaired cerebrovascular function in diabetes.
Abdelsaid, M; Coucha, M; Ergul, A; Ma, H, 2014
)
0.4
"After establishing dose-response curves of both compounds in conscious, hypertensive Dahl salt-sensitive and pulmonary hypertensive bleomycin-treated rats, macitentan was administered on top of the maximal effective dose of bosentan."( Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
Bortolamiol, C; Bossu, A; Clozel, M; Hess, P; Iglarz, M; Rey, M; Wanner, D, 2014
)
0.4
" The PK profile supports a once-a-day dosing regimen."( Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Dingemanse, J; Krähenbühl, S; Sidharta, PN, 2015
)
0.42
" Bosentan was started at a dosage of 125 mg per day (62."( Surgical Closure of Atrial Septal Defect with High Pulmonary Vascular Resistance--A Case Report.
Adhikary, AB; Aftabuddin, M; Ahmed, I; Khan, OS; Rahman, MA, 2016
)
0.43
"Oral dosing with bosentan and tadalafil in children may not achieve therapeutic blood concentration."( Pharmacokinetics of drugs for pediatric pulmonary hypertension.
Azuma, H; Kajihama, A; Kajino, H; Kamiyama, N; Maeda, J; Nakau, K; Oka, H; Sugimoto, M; Tasaki, Y; Yamagishi, H, 2016
)
0.43
" The intent of this review is manifold: a) to summarize the physiological role of CYP enzymes and hepatic-biliary transporters; b) to discuss the mechanism(s) involved in the purported liver injury caused by bosentan; c) to tabulate the numerous clinical drug-drug interaction studies involving the physiological interplay with CYP and/or transporters; d) to provide some perspectives on dosing strategy of bosentan."( Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: Physiological role of enzymes and transporters.
Srinivas, NR, 2016
)
0.43
"FUTURE-3, a phase III pediatric pharmacokinetic (PK) trial conducted to compare 2 bosentan dosing regimens in 64 patients with pulmonary arterial hypertension, offered the opportunity to compare dried blood spot (DBS)-derived data to plasma data."( Bosentan Pharmacokinetics in Pediatric Patients with Pulmonary Arterial Hypertension: Comparison of Dried Blood Spot and Plasma Analysis.
Dingemanse, J; Géhin, M; Sidharta, PN, 2016
)
0.43
"The objective of the present study was to develop an optimal equation for the pediatric dose-response relationship of warfarin using a size parameter with an exponent of body weight (SIZE) which has been proposed for scaling drug clearance."( A model analysis for dose-response relationship of warfarin in Japanese children: An introduction of the SIZE parameter.
Hirono, K; Ichida, F; Nakamura, S; Ozawa, S; Taguchi, M; Watanabe, N; Yoshimura, N, 2016
)
0.43
"PAH patients receiving a stable combination treatment with ERA and PDE-5i with targeted dosage for at least 1 month were routinely assessed, including clinical parameters and plasma drug concentrations."( Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Benjamin, N; Burhenne, J; Egenlauf, B; Enderle, Y; Fischer, C; Grünig, E; Haefeli, WE; Harutyunova, S; Huppertz, A; Klose, H; Ohnesorge, J, 2017
)
0.46
" But the solubility and bioavailability of this drug are poor, which has restricted the design and development of dosage forms for efficient and successful therapy."( Effect of amphiphilic graft co-polymer-carrier on physical stability of bosentan nanocomposite: Assessment of solubility, dissolution and bioavailability.
Chaudhari, PD; Kendre, PN, 2018
)
0.48
" The range of applications of the UHPLC in the analysis of pharmaceutical substances and dosage forms is currently extensively discussed."( THE COMPARISON OF THE STABILITY INDICATING TWO HPLC METHODS AND THEIR APPLICATION FOR THE DETERMINATION OF BOSENTAN IN COATED TABLETS.
Kutner, A; Pesta, E; Sidoryk, K; Wicherkiewicz, S; Zielińska, A; Łuniewski, W, 2016
)
0.43
" The current PBPK model, which considers changes in unbound potency-adjusted active species, can be used to inform dosing recommendations when abemaciclib is coadministered with CYP3A4 perpetrators."( Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
Dickinson, GL; Hall, SD; Kulanthaivel, P; Morse, BL; Posada, MM; Turner, PK, 2020
)
0.56
" PK data from the studies were pooled to develop a pediatric population PK model for tadalafil that characterized relationships among dose, exposure, and the effects of covariates with an aim to develop a population PK model that could simulate concentration-time profiles and assess exposure-matched dosing strategies in a pediatric PAH population."( Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.
Ferguson-Sells, L; Li, B; Small, D; Velez de Mendizabal, N, 2022
)
0.72
" The model demonstrated that plasma tadalafil concentrations in pediatric patients aged 2 to < 18 years were similar to those in adults at similar doses, and confirmed that dosing of 40 mg once daily in pediatric patients with a bodyweight ≥ 40 kg, and a dose of 20 mg once daily in patients with a body weight < 40 kg and aged ≥ 2 years are suitable for phase III evaluation."( Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.
Ferguson-Sells, L; Li, B; Small, D; Velez de Mendizabal, N, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
endothelin receptor antagonistA hormone antagonist that blocks endothelin receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
pyrimidinesAny compound having a pyrimidine as part of its structure.
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (36)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency56.23410.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency20.60870.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency14.96010.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency23.35940.000221.22318,912.5098AID743035; AID743053; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency34.38320.000657.913322,387.1992AID1259377; AID1259378
progesterone receptorHomo sapiens (human)Potency33.49150.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency11.76100.01237.983543.2770AID1346984; AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency29.84930.003041.611522,387.1992AID1159552
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency26.60320.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency9.26710.005428.02631,258.9301AID1346982; AID1346985
GVesicular stomatitis virusPotency27.54040.01238.964839.8107AID1645842
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency26.60110.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency33.48890.023723.228263.5986AID743222
activating transcription factor 6Homo sapiens (human)Potency0.21310.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency30.10650.057821.109761.2679AID1159526
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency28.18380.354828.065989.1251AID504847
heat shock protein beta-1Homo sapiens (human)Potency33.48890.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency33.48890.000627.21521,122.0200AID743202
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2551
Interferon betaHomo sapiens (human)Potency27.54040.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)42.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)22.00000.20005.677410.0000AID1473741
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)30.60000.40002.75008.6000AID1209456
Bile salt export pumpRattus norvegicus (Norway rat)Ki12.00000.30003.10006.1000AID680333
Bile salt export pumpHomo sapiens (human)IC50 (µMol)27.48000.11007.190310.0000AID1209455; AID1443980; AID1443986; AID1449628; AID1473738
Endothelin receptor type BRattus norvegicus (Norway rat)IC50 (µMol)0.09500.00001.17444.4000AID1192698
Endothelin receptor type BHomo sapiens (human)IC50 (µMol)0.30440.00010.65659.8000AID1323193; AID1573505; AID1626368; AID1626375; AID1631612; AID66528; AID699136
Endothelin receptor type BHomo sapiens (human)Ki0.21000.00010.05430.3710AID66360; AID66690
Endothelin-1 receptorHomo sapiens (human)IC50 (µMol)0.23170.00000.76479.9000AID1323192; AID1573504; AID1626367; AID1626374; AID1631611; AID671490; AID68322; AID699137
Endothelin-1 receptorHomo sapiens (human)Ki0.00730.00000.430010.0000AID68296; AID68487
Endothelin-1 receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00470.00001.774610.0000AID1192697
Endothelin-1 receptorRattus norvegicus (Norway rat)Ki0.00650.00000.00210.0065AID66210
Deoxyhypusine synthaseHomo sapiens (human)IC50 (µMol)60.83000.14000.78671.7200AID1820366
Sodium/bile acid cotransporterHomo sapiens (human)IC50 (µMol)30,000.00001.00005.92679.6000AID1600824
Endothelin-1 receptorSus scrofa (pig)IC50 (µMol)0.00750.00020.61372.9000AID68635
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)11.86670.00203.519610.0000AID1215086; AID1215087; AID1215094
Endothelin receptor type BHomo sapiens (human)Kd0.07240.07240.07240.0724AID66338
Endothelin-1 receptorRattus norvegicus (Norway rat)Kd0.05610.03980.63442.3442AID1626369; AID66338
Endothelin receptor type BBos taurus (cattle)Kd0.07240.07240.07240.0724AID66338
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (207)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIEndothelin receptor type BHomo sapiens (human)
neural crest cell migrationEndothelin receptor type BHomo sapiens (human)
positive regulation of protein phosphorylationEndothelin receptor type BHomo sapiens (human)
renin secretion into blood streamEndothelin receptor type BHomo sapiens (human)
regulation of heart rateEndothelin receptor type BHomo sapiens (human)
regulation of pHEndothelin receptor type BHomo sapiens (human)
cell surface receptor signaling pathwayEndothelin receptor type BHomo sapiens (human)
negative regulation of adenylate cyclase activityEndothelin receptor type BHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEndothelin receptor type BHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEndothelin receptor type BHomo sapiens (human)
nervous system developmentEndothelin receptor type BHomo sapiens (human)
peripheral nervous system developmentEndothelin receptor type BHomo sapiens (human)
posterior midgut developmentEndothelin receptor type BHomo sapiens (human)
positive regulation of cell population proliferationEndothelin receptor type BHomo sapiens (human)
gene expressionEndothelin receptor type BHomo sapiens (human)
negative regulation of neuron maturationEndothelin receptor type BHomo sapiens (human)
response to organic cyclic compoundEndothelin receptor type BHomo sapiens (human)
vein smooth muscle contractionEndothelin receptor type BHomo sapiens (human)
calcium-mediated signalingEndothelin receptor type BHomo sapiens (human)
cGMP-mediated signalingEndothelin receptor type BHomo sapiens (human)
heparin metabolic processEndothelin receptor type BHomo sapiens (human)
melanocyte differentiationEndothelin receptor type BHomo sapiens (human)
regulation of fever generationEndothelin receptor type BHomo sapiens (human)
aldosterone metabolic processEndothelin receptor type BHomo sapiens (human)
enteric smooth muscle cell differentiationEndothelin receptor type BHomo sapiens (human)
positive regulation of urine volumeEndothelin receptor type BHomo sapiens (human)
renal sodium excretionEndothelin receptor type BHomo sapiens (human)
epithelial fluid transportEndothelin receptor type BHomo sapiens (human)
vasoconstrictionEndothelin receptor type BHomo sapiens (human)
vasodilationEndothelin receptor type BHomo sapiens (human)
negative regulation of apoptotic processEndothelin receptor type BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionEndothelin receptor type BHomo sapiens (human)
macrophage chemotaxisEndothelin receptor type BHomo sapiens (human)
response to painEndothelin receptor type BHomo sapiens (human)
enteric nervous system developmentEndothelin receptor type BHomo sapiens (human)
regulation of epithelial cell proliferationEndothelin receptor type BHomo sapiens (human)
negative regulation of protein metabolic processEndothelin receptor type BHomo sapiens (human)
canonical Wnt signaling pathwayEndothelin receptor type BHomo sapiens (human)
positive regulation of penile erectionEndothelin receptor type BHomo sapiens (human)
establishment of endothelial barrierEndothelin receptor type BHomo sapiens (human)
renal sodium ion absorptionEndothelin receptor type BHomo sapiens (human)
calcium ion transmembrane transportEndothelin receptor type BHomo sapiens (human)
cellular response to lipopolysaccharideEndothelin receptor type BHomo sapiens (human)
protein transmembrane transportEndothelin receptor type BHomo sapiens (human)
podocyte differentiationEndothelin receptor type BHomo sapiens (human)
endothelin receptor signaling pathwayEndothelin receptor type BHomo sapiens (human)
renal albumin absorptionEndothelin receptor type BHomo sapiens (human)
neuroblast migrationEndothelin receptor type BHomo sapiens (human)
chordate pharynx developmentEndothelin receptor type BHomo sapiens (human)
response to sodium phosphateEndothelin receptor type BHomo sapiens (human)
response to endothelinEndothelin receptor type BHomo sapiens (human)
developmental pigmentationEndothelin receptor type BHomo sapiens (human)
mitotic cell cycleEndothelin-1 receptorHomo sapiens (human)
branching involved in blood vessel morphogenesisEndothelin-1 receptorHomo sapiens (human)
response to hypoxiaEndothelin-1 receptorHomo sapiens (human)
in utero embryonic developmentEndothelin-1 receptorHomo sapiens (human)
blood vessel remodelingEndothelin-1 receptorHomo sapiens (human)
response to amphetamineEndothelin-1 receptorHomo sapiens (human)
regulation of heart rateEndothelin-1 receptorHomo sapiens (human)
glomerular filtrationEndothelin-1 receptorHomo sapiens (human)
cardiac chamber formationEndothelin-1 receptorHomo sapiens (human)
left ventricular cardiac muscle tissue morphogenesisEndothelin-1 receptorHomo sapiens (human)
atrial cardiac muscle tissue developmentEndothelin-1 receptorHomo sapiens (human)
cardiac neural crest cell migration involved in outflow tract morphogenesisEndothelin-1 receptorHomo sapiens (human)
noradrenergic neuron differentiationEndothelin-1 receptorHomo sapiens (human)
intracellular calcium ion homeostasisEndothelin-1 receptorHomo sapiens (human)
smooth muscle contractionEndothelin-1 receptorHomo sapiens (human)
mitochondrion organizationEndothelin-1 receptorHomo sapiens (human)
signal transductionEndothelin-1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayEndothelin-1 receptorHomo sapiens (human)
activation of adenylate cyclase activityEndothelin-1 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayEndothelin-1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEndothelin-1 receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEndothelin-1 receptorHomo sapiens (human)
respiratory gaseous exchange by respiratory systemEndothelin-1 receptorHomo sapiens (human)
regulation of blood pressureEndothelin-1 receptorHomo sapiens (human)
cell population proliferationEndothelin-1 receptorHomo sapiens (human)
response to woundingEndothelin-1 receptorHomo sapiens (human)
gene expressionEndothelin-1 receptorHomo sapiens (human)
protein kinase A signalingEndothelin-1 receptorHomo sapiens (human)
regulation of glucose transmembrane transportEndothelin-1 receptorHomo sapiens (human)
neural crest cell fate commitmentEndothelin-1 receptorHomo sapiens (human)
artery smooth muscle contractionEndothelin-1 receptorHomo sapiens (human)
neuron remodelingEndothelin-1 receptorHomo sapiens (human)
heparin metabolic processEndothelin-1 receptorHomo sapiens (human)
thyroid gland developmentEndothelin-1 receptorHomo sapiens (human)
cellular response to oxidative stressEndothelin-1 receptorHomo sapiens (human)
embryonic heart tube developmentEndothelin-1 receptorHomo sapiens (human)
aorta developmentEndothelin-1 receptorHomo sapiens (human)
vasoconstrictionEndothelin-1 receptorHomo sapiens (human)
norepinephrine metabolic processEndothelin-1 receptorHomo sapiens (human)
middle ear morphogenesisEndothelin-1 receptorHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionEndothelin-1 receptorHomo sapiens (human)
cellular response to human chorionic gonadotropin stimulusEndothelin-1 receptorHomo sapiens (human)
enteric nervous system developmentEndothelin-1 receptorHomo sapiens (human)
sympathetic nervous system developmentEndothelin-1 receptorHomo sapiens (human)
axon extensionEndothelin-1 receptorHomo sapiens (human)
embryonic skeletal system developmentEndothelin-1 receptorHomo sapiens (human)
neuromuscular processEndothelin-1 receptorHomo sapiens (human)
sodium ion homeostasisEndothelin-1 receptorHomo sapiens (human)
canonical Wnt signaling pathwayEndothelin-1 receptorHomo sapiens (human)
face developmentEndothelin-1 receptorHomo sapiens (human)
axonogenesis involved in innervationEndothelin-1 receptorHomo sapiens (human)
establishment of endothelial barrierEndothelin-1 receptorHomo sapiens (human)
pharyngeal arch artery morphogenesisEndothelin-1 receptorHomo sapiens (human)
renal sodium ion absorptionEndothelin-1 receptorHomo sapiens (human)
calcium ion transmembrane transportEndothelin-1 receptorHomo sapiens (human)
cellular response to follicle-stimulating hormone stimulusEndothelin-1 receptorHomo sapiens (human)
cellular response to luteinizing hormone stimulusEndothelin-1 receptorHomo sapiens (human)
protein transmembrane transportEndothelin-1 receptorHomo sapiens (human)
glomerular endothelium developmentEndothelin-1 receptorHomo sapiens (human)
podocyte differentiationEndothelin-1 receptorHomo sapiens (human)
endothelin receptor signaling pathway involved in heart processEndothelin-1 receptorHomo sapiens (human)
renal albumin absorptionEndothelin-1 receptorHomo sapiens (human)
vascular associated smooth muscle cell developmentEndothelin-1 receptorHomo sapiens (human)
mesenchymal cell apoptotic processEndothelin-1 receptorHomo sapiens (human)
sympathetic neuron axon guidanceEndothelin-1 receptorHomo sapiens (human)
semaphorin-plexin signaling pathway involved in axon guidanceEndothelin-1 receptorHomo sapiens (human)
podocyte apoptotic processEndothelin-1 receptorHomo sapiens (human)
meiotic cell cycle process involved in oocyte maturationEndothelin-1 receptorHomo sapiens (human)
cranial skeletal system developmentEndothelin-1 receptorHomo sapiens (human)
response to acetylcholineEndothelin-1 receptorHomo sapiens (human)
regulation of protein localization to cell leading edgeEndothelin-1 receptorHomo sapiens (human)
positive regulation of cation channel activityEndothelin-1 receptorHomo sapiens (human)
endothelin receptor signaling pathwayEndothelin-1 receptorHomo sapiens (human)
developmental pigmentationEndothelin-1 receptorHomo sapiens (human)
regulation of blood pressureEndothelin receptor type BBos taurus (cattle)
calcium-mediated signalingEndothelin receptor type BBos taurus (cattle)
enteric nervous system developmentEndothelin receptor type BBos taurus (cattle)
endothelin receptor signaling pathwayEndothelin receptor type BBos taurus (cattle)
translationDeoxyhypusine synthaseHomo sapiens (human)
spermidine metabolic processDeoxyhypusine synthaseHomo sapiens (human)
positive regulation of cell population proliferationDeoxyhypusine synthaseHomo sapiens (human)
peptidyl-lysine modification to peptidyl-hypusineDeoxyhypusine synthaseHomo sapiens (human)
positive regulation of T cell proliferationDeoxyhypusine synthaseHomo sapiens (human)
glucose homeostasisDeoxyhypusine synthaseHomo sapiens (human)
spermidine catabolic processDeoxyhypusine synthaseHomo sapiens (human)
sodium ion transportSodium/bile acid cotransporterHomo sapiens (human)
response to organic cyclic compoundSodium/bile acid cotransporterHomo sapiens (human)
bile acid and bile salt transportSodium/bile acid cotransporterHomo sapiens (human)
response to nutrient levelsSodium/bile acid cotransporterHomo sapiens (human)
bile acid signaling pathwaySodium/bile acid cotransporterHomo sapiens (human)
response to estrogenSodium/bile acid cotransporterHomo sapiens (human)
response to ethanolSodium/bile acid cotransporterHomo sapiens (human)
symbiont entry into host cellSodium/bile acid cotransporterHomo sapiens (human)
transmembrane transportSodium/bile acid cotransporterHomo sapiens (human)
cellular response to xenobiotic stimulusSodium/bile acid cotransporterHomo sapiens (human)
regulation of bile acid secretionSodium/bile acid cotransporterHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (54)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endothelin receptor activityEndothelin receptor type BHomo sapiens (human)
protein bindingEndothelin receptor type BHomo sapiens (human)
peptide hormone bindingEndothelin receptor type BHomo sapiens (human)
type 1 angiotensin receptor bindingEndothelin receptor type BHomo sapiens (human)
phosphatidylinositol phospholipase C activityEndothelin-1 receptorHomo sapiens (human)
endothelin receptor activityEndothelin-1 receptorHomo sapiens (human)
protein bindingEndothelin-1 receptorHomo sapiens (human)
endothelin receptor activityEndothelin receptor type BBos taurus (cattle)
protein bindingDeoxyhypusine synthaseHomo sapiens (human)
deoxyhypusine synthase activityDeoxyhypusine synthaseHomo sapiens (human)
identical protein bindingDeoxyhypusine synthaseHomo sapiens (human)
virus receptor activitySodium/bile acid cotransporterHomo sapiens (human)
protein bindingSodium/bile acid cotransporterHomo sapiens (human)
bile acid:sodium symporter activitySodium/bile acid cotransporterHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneEndothelin receptor type BHomo sapiens (human)
nuclear membraneEndothelin receptor type BHomo sapiens (human)
plasma membraneEndothelin receptor type BHomo sapiens (human)
plasma membraneEndothelin-1 receptorHomo sapiens (human)
plasma membraneEndothelin-1 receptorHomo sapiens (human)
plasma membraneEndothelin receptor type BBos taurus (cattle)
cytosolDeoxyhypusine synthaseHomo sapiens (human)
cytoplasmDeoxyhypusine synthaseHomo sapiens (human)
plasma membraneSodium/bile acid cotransporterHomo sapiens (human)
basolateral plasma membraneSodium/bile acid cotransporterHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (210)

Assay IDTitleYearJournalArticle
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1626368Displacement of radioligand from ETB receptor in human placenta cell membranes2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1698000Apparent permeability in dog MDCKII-LE cells at pH 7.4
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1323173Retention time of the compound2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID1698011Fraction unbound in human plasma
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID68635In vitro inhibition of [125 I]ET-1 binding to Endothelin A receptor in porcine aortic membrane.2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Modifications and structure-activity relationships at the 2-position of 4-sulfonamidopyrimidine derivatives as potent endothelin antagonists.
AID1323137Drug metabolism assessed as human recombinant CYP3A4-mediated metabolite formation by measuring parent compound remaining at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID1820366Inhibition of DHPS (unknown origin ) incubated for 30 mins by NAD/NADH-Glow assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID699131Antihypertensive activity in telemeterized hypertensive Dahl salt-sensitive rat assessed as reduction in mean arterial blood pressure at 100 mg/kg, po measured over 6 hrs2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1215094Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1222793Dissociation constant, pKa of the compound2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID1600824Inhibition of NTCP in human hepatocytes assessed as reduction in Na+-dependent [3H]taurocholate uptake measured at 45s following compound addition by liquid scintillation counting method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Design, synthesis and biological evaluation of benzamide derivatives as novel NTCP inhibitors that induce apoptosis in HepG2 cells.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1698004Fraction unbound in cynomolgus monkey plasma
AID1698006Ratio of drug level in cynomolgus monkey blood to plasma administered through iv dosing by LC-MS/MS analysis
AID699137Displacement of [I125]ET1 from recombinant ETA receptor expressed in CHO cells after 2 hrs by TopCount analysis2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
AID1474005Ratio of drug concentration at steady state in human at 62.5 to 125 mg, po BID after 12 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID66853Ratio of binding to Endothelin A and Endothelin B receptors1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.
AID1474001AUC in human at 62.5 to 125 mg, po BID after 12 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID68296Ability to displace endothelin ([125I]ET1) from human Endothelin A receptor1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.
AID1192699Selectivity ratio of IC50 for rat ETB receptor to IC50 for rat ETA receptor2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity.
AID1323139Drug metabolism in human liver microsomes assessed as formation of 4-(1-hydroxy-2-methylpropan-2-yl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID68487Inhibitory activity against human endothelin A receptor expressed in CHO cells2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective
AID1215093Activation of rat PXR expressed in human HepG2 cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID66360Ability to displace endothelin ([125I]ET1) from human Endothelin B receptor1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.
AID1598497Anti-hypersensitive activity in MCT-induced pulmonary arterial hypertension Sprague-Dawley rat model assessed as reduction in mean pulmonary artery pressure at 100 mg/kg administered once daily for 21 days starting from 21 days post-MCT challenge by right2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
AID1323138Drug metabolism assessed as human recombinant CYP2C9-mediated metabolite formation by measuring parent compound remaining at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID21857In vivo clearance in human.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1323174Drug metabolism assessed as human recombinant CYP2D6-mediated metabolite formation by measuring parent compound remaining at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID699129Effect on heart rate in telemeterized hypertensive Dahl salt-sensitive rat at 3 mg/kg, po2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID172169Compound was tested for inhibition of big ET-induced blood pressure increase in drug treated rats with LU 135252 and balanced ETA/B receptor antagonists at 10 mg/kg oral dose, 2 hr pretreatment1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Discovery and synthesis of (S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), a novel orally active mixed ET(A)/ET(B) receptor antagonist.
AID1697999Dissociation constant, acidic pKa of compound measured up to 18 mins by capillary electrophoresis
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1573504Antagonist activity at ETA receptor (unknown origin) assessed as increase in G protein-mediated vasoconstriction2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID25914Half-life is obtained after intravenous dosing of rats.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.
AID28211cLogP of the compound; ND means not determined2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1323192Binding affinity to human ETA receptor2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID1598495Anti-hypersensitive activity in MCT-induced pulmonary arterial hypertension Sprague-Dawley rat model assessed as reduction in mean pulmonary artery pressure at 1 mg/kg administered once daily for 21 days starting from 21 days post-MCT challenge by right c2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1473835Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID680333TP_TRANSPORTER: inhibition of Taurocholate uptake in membrane vesicle from Bsep-expressing Sf9-cell2001Clinical pharmacology and therapeutics, Apr, Volume: 69, Issue:4
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.
AID1573506Antagonist activity at ETB receptor (unknown origin) assessed as effect on beta-arrestin recruitment2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID1323193Binding affinity to human ETB receptor2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID1698007Ratio of drug level in human blood to plasma administered through iv dosing by LC-MS/MS analysis
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1474004Ratio of drug concentration at steady state in human at 62.5 to 125 mg, po BID after 12 hrs to IC50 for human MRP3 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID21854In vivo clearance in dog.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID21851In vitro clearance in human in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1820369Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1323175Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 24 hrs by MTT assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1573537Antagonist activity at ETA receptor (unknown origin) beta-arrestin recruitment assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1215087Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1631611Antagonist activity at ET-A receptor (unknown origin)2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1323136Metabolic stability in human liver microsomes assessed as parent compound remaining at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID169565Area between curve calculated after 30 mg/kg of oral dosing in hypertensive Dahl salt sensitive rats by recording blood pressure and heart rate2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists.
AID1698002Intrinsic clearance in cryopreserved human hepatocytes at 1 uM measured up to 120 mins by LC-MS/MS analysis
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1820368Cytotoxicity against mouse B16 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1698010Hepatic clearance in human administered through iv dosing
AID1323141Drug metabolism in human liver microsomes assessed as formation of 4-(1-hydroxy-2-methylpropan-2-yl)-N-(6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID603845Inhibition of endothelin A receptor in New Zealand white rabbit aortic rings assessed as inhibition of endothelin-1-induced vascular contraction at 10'-6 M2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Synthesis and in vitro evaluation of ambrisentan analogues as potential endothelin receptor antagonists.
AID1323151Drug metabolism assessed as human recombinant CYP3A4-mediated formation of 4-tert-butyl-N-(6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID699130Antihypertensive activity in telemeterized hypertensive Dahl salt-sensitive rat assessed as duration of mean arterial blood pressure lowering action at 100 mg/kg, po2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
AID1598496Anti-hypersensitive activity in MCT-induced pulmonary arterial hypertension Sprague-Dawley rat model assessed as reduction in mean pulmonary artery pressure at 25 mg/kg administered once daily for 21 days starting from 21 days post-MCT challenge by right 2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
AID699133Antihypertensive activity in telemeterized hypertensive Dahl salt-sensitive rat assessed as reduction in mean arterial blood pressure at 3 mg/kg, po measured over 6 hrs2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID671490Antagonist activity at human endothelin receptor subtype A expressed in CHO-K1 cells2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Synthesis and biological evaluation of 4'-[(benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide derivatives as dual angiotensin II/endothelin A receptor antagonists.
AID1254756Intrinsic clearance in rat liver microsomes2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Applications of Fluorine in Medicinal Chemistry.
AID699132Antihypertensive activity in telemeterized hypertensive Dahl salt-sensitive rat assessed as duration of mean arterial blood pressure lowering action at 3 mg/kg, po2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
AID1626375Displacement of 125I-ET1 from human placenta ETB receptor2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1820370Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay2021Journal of medicinal chemistry, 09-23, Volume: 64, Issue:18
Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation.
AID166800In vitro inhibition of ET-1 induced contractions in rabbit carotid artery rings2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective
AID1323140Drug metabolism in human liver microsomes assessed as formation of 4-tert-butyl-N-(6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID1474002Drug concentration at steady state in human at 62.5 to 125 mg, po BID after 12 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1443986Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell membrane vesicles assessed as reduction in ATP or AMP-dependent [3H]-taurocholic acid uptake in to vesicles preincubated for 5 mins followed by ATP/AMP addition measured after2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1461777Antagonist activity at New Zealand rabbit endothelin A/B2 receptor assessed as dilation of endothelin-1 induced basilary artery contraction measured after 20 mins
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1573505Antagonist activity at ETB receptor (unknown origin) assessed as effect on G protein-mediated smooth muscle contraction2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1698008Hepatic clearance in Wistar Hannover rat at 1 mg/kg, iv
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1215095Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay relative to SR128132011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1626369Antagonist activity at rat aortic ring ETA receptor in presence of ET12016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1698005Ratio of drug level in Wistar Hannover rat blood to plasma administered through iv dosing by LC-MS/MS analysis
AID18193Oral bioavailability in rat1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID21859In vivo clearance in rat.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID172168Compound was tested for %reduction of big ET-induced blood pressure increase in drug treated rats with LU 135252 and balanced ETA/B receptor antagonists at 10 mg/kg oral dose, 2 hr pretreatment1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Discovery and synthesis of (S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2- (4,6-dimethylpyrimidin-2-yloxy)-3,3-diphenylpropionic acid (LU 302872), a novel orally active mixed ET(A)/ET(B) receptor antagonist.
AID1698001Lipophilicity, log D of the compound at pH 7.4 by by shake flask method
AID68322In vitro inhibitory concentration required against [125I]ET1 binding to membranes of CHO cells expressing human ETA receptor2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID66338Potency on ETA receptor assessed by inhibition of the contraction induced by ET-1 in rat aortic rings2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists.
AID66690Inhibitory activity against human endothelin B receptor expressed in CHO cells2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1626374Displacement of 125I-ET1 from human smooth muscle ETA receptor2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1323160Drug metabolism assessed as human recombinant CYP2C9-mediated formation of 4-(1-hydroxy-2-methylpropan-2-yl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analys2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID1698003Fraction unbound in rat plasma
AID1215096Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID66528In vitro inhibitory concentration required against [125I]ET1 binding to membranes of CHO cells expressing human ETB receptor2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
The use of sulfonylamido pyrimidines incorporating an unsaturated side chain as endothelin receptor antagonists.
AID1323150Drug metabolism assessed as human recombinant CYP3A4-mediated formation of 4-(1-hydroxy-2-methylpropan-2-yl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analys2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID699136Displacement of [I125]ET1 from recombinant ETB receptor expressed in CHO cells after 2 hrs by TopCount analysis2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
AID1631612Antagonist activity at ET-B receptor (unknown origin)2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.
AID1192697Displacement of [125I]ET-1 from rat ETA receptor after 1 hr by Lowry method2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity.
AID1215086Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID21852In vitro clearance in rat in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1323152Drug metabolism assessed as human recombinant CYP3A4-mediated formation of 4-(1-hydroxy-2-methylpropan-2-yl)-N-(6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analys2016European journal of medicinal chemistry, Oct-04, Volume: 121Metabolism study and biological evaluation of bosentan derivatives.
AID66210Binding affinity towards Endothelin A receptor2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
AID1631614Binding affinity to ET-A receptor (unknown origin) assessed as dissociation half life2016Journal of medicinal chemistry, 09-22, Volume: 59, Issue:18
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.
AID1698009Hepatic clearance in cynomolgus monkey at < 1 mg/kg, iv administered as cassette dosing
AID1215089Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID66198Displacement of [125I]ET-1 from Endothelin A receptor2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474003Ratio of drug concentration at steady state in human at 62.5 to 125 mg, po BID after 12 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID28194Permeability was assessed in caco-2 cell assay; ND means not determined2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective
AID1192698Displacement of [125I]ET-1 from rat ETB receptor after 1 hr by Lowry method2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID66214Selectivity for endothelin A receptor over endothelin receptor B2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
AID1626367Displacement of radioligand from ETA receptor (unknown origin) expressed in fall armyworm sf9 cell membranes2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.
AID12755Compound was evaluated for oral bioavailability in rats; 30-802004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.
AID21849In vitro clearance in dog in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1345868Rat ETA receptor (Endothelin receptors)1994The Journal of pharmacology and experimental therapeutics, Jul, Volume: 270, Issue:1
Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
AID1345853Rat ETB receptor (Endothelin receptors)1994The Journal of pharmacology and experimental therapeutics, Jul, Volume: 270, Issue:1
Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
AID1345807Human ETB receptor (Endothelin receptors)2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,738)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's260 (14.96)18.2507
2000's747 (42.98)29.6817
2010's640 (36.82)24.3611
2020's91 (5.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 7.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index7.09 (24.57)
Research Supply Index7.63 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (7.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials215 (11.71%)5.53%
Reviews277 (15.09%)6.00%
Case Studies247 (13.45%)4.05%
Observational18 (0.98%)0.25%
Other1,079 (58.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]